Program Description
The approvals of Janus-associated kinase (JAK) inhibitors reshaped the treatment landscape for patients with myelofibrosis (MF), but their potential for adverse effects often limits their use over time. Additional agents under development present alternative options for patients with relapsed/refractory MF or who are not eligible for treatment with JAK inhibitors. Managed care pharmacists involved in formulary development must be familiar with these expanding treatment options for patients with MF. This activity is a continuation of the clinical data and emerging treatment strategies examined at the 2023 AMCP Annual Meeting session titled “New Pathways in Care for Myelofibrosis: Optimizing Treatment to Improve Outcomes.” Expert faculty will build on information presented with a discussion of the cost of care in MF and the impact of investigational targeted therapies on patient quality of life.
Target audience: Managed care pharmacists and oncology pharmacists
Type of activity: Application
Release date: April 26, 2023
Expiration date: June 26, 2023
Time to complete activity: 1.0 hour
Learner level: Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Differentiate risk factors and comorbidities that affect treatment, quality of life, and outcomes for patients with myelofibrosis (MF)
- Investigate clinical data for use of JAK inhibitors and targeted therapies under investigation for the management of MF
- Identify opportunities for managed care pharmacists to support access and appropriate use of new and emerging therapeutic options to improve outcomes in patients with MF
Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP
Clinical Oncology Pharmacy Manager
Levine Cancer Institute, Atrium Health
Charlotte, North Carolina
James Davis, PharmD, BCOP
Medical Writer for Panel Discussion and Animation Videos
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-23-121-L01-P. The activity is available for CE credit through June 26, 2023.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Donald Moore, PharmD, BCPS, BCOP, DPLA, FCCP, has the following financial relationships with commercial interests to disclose:
Consultant: Pfizer, AstraZeneca, Janssen
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
James Davis, PharmD, BCOP
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Amy H. Seung, PharmD, BCOP, FHOPA, CHCP; Evelina Kolychev, PharmD, BCOP; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms